Top ▲
Target not currently curated in GtoImmuPdb
Target id: 1791
Nomenclature: activin A receptor type 2A
Abbreviated Name: ActR2
Quaternary Structure: Complexes |
Bone morphogenetic protein receptors |
Growth/differentiation factor receptors |
Activin receptors |
Gene and Protein Information | ||||||
Species | TM | AA | Chromosomal Location | Gene Symbol | Gene Name | Reference |
Human | 1 | 513 | 2q22.3-q23.1 | ACVR2A | activin A receptor type 2A | |
Mouse | 1 | 513 | 2 28.38 cM | Acvr2a | activin receptor IIA | |
Rat | 1 | 513 | 3q12 | Acvr2a | activin A receptor type 2A |
Previous and Unofficial Names |
activin A receptor, type II | activin receptor IIA | ActRIIa | activin receptor 2A | ACVR2 | activin A receptor type IIA |
Database Links | |
Alphafold | P27037 (Hs), P27038 (Mm), P38444 (Rn) |
BRENDA | 2.7.11.30 |
ChEMBL Target | CHEMBL5616 (Hs) |
Ensembl Gene | ENSG00000121989 (Hs), ENSMUSG00000052155 (Mm), ENSRNOG00000005334 (Rn) |
Entrez Gene | 92 (Hs), 11480 (Mm), 29263 (Rn) |
Human Protein Atlas | ENSG00000121989 (Hs) |
KEGG Enzyme | 2.7.11.30 |
KEGG Gene | hsa:92 (Hs), mmu:11480 (Mm), rno:29263 (Rn) |
OMIM | 102581 (Hs) |
Pharos | P27037 (Hs) |
RefSeq Nucleotide | NM_001616 (Hs), NM_007396 (Mm), NM_031571 (Rn) |
RefSeq Protein | NP_001607 (Hs), NP_031422 (Mm), NP_113759 (Rn) |
UniProtKB | P27037 (Hs), P27038 (Mm), P38444 (Rn) |
Wikipedia | ACVR2A (Hs) |
Selected 3D Structures | |||||||||||||
|
Enzyme Reaction | ||||
|
Natural/Endogenous Ligands |
myostatin {Sp: Human} |
Comments: Endogenous ligands may include growth/differentiation factor-6 [1]. |
Download all structure-activity data for this target as a CSV file
Antibodies | |||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||
|
DiscoveRx KINOMEscan® screen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
A screen of 72 inhibitors against 456 human kinases. Quantitative data were derived using DiscoveRx KINOMEscan® platform. http://www.discoverx.com/services/drug-discovery-development-services/kinase-profiling/kinomescan Reference: 3-4 |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Target used in screen: ACVR2A | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Displaying the top 10 most potent ligands View all ligands in screen » |
1. Asai-Coakwell M, March L, Dai XH, Duval M, Lopez I, French CR, Famulski J, De Baere E, Francis PJ, Sundaresan P et al.. (2013) Contribution of growth differentiation factor 6-dependent cell survival to early-onset retinal dystrophies. Hum Mol Genet, 22 (7): 1432-42. [PMID:23307924]
2. Berger C, Herrmann T, Lu C, Sheppard K-A, Trifilieff E, Urlinger S. (2013) Compositions and methods for increasing muscle growth. Patent number: US8388968. Assignee: Novartis Ag. Priority date: 27/04/2009. Publication date: 05/03/2013.
3. Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, Hocker M, Treiber DK, Zarrinkar PP. (2011) Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol, 29 (11): 1046-51. [PMID:22037378]
4. Wodicka LM, Ciceri P, Davis MI, Hunt JP, Floyd M, Salerno S, Hua XH, Ford JM, Armstrong RC, Zarrinkar PP et al.. (2010) Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry. Chem Biol, 17 (11): 1241-9. [PMID:21095574]
Type II receptor serine/threonine kinases: activin A receptor type 2A. Last modified on 30/03/2016. Accessed on 04/12/2024. IUPHAR/BPS Guide to PHARMACOLOGY, https://www.guidetoimmunopharmacology.org/GRAC/ObjectDisplayForward?objectId=1791.